About

This innovative B2B event will enable the participants to learn about the latest trends, developments, business models and strategies in the companion diagnostics.

Companion diagnostic co-development has the potential to significantly alter the drug development process and commercialization of drug candidates by yielding safer drugs with enhanced therapeutic efficacy in a faster, more cost-effective manner.

This year, for the first time, the companion diagnostic community will meet to analyse and tackle the latest and greatest opportunities in the CDx. In this Summit you will learn more about doing partnership and commercialize CDx tests with pharmaceutical and biotech companies. We will also provide solutions to assist in all stages of CDx development from the biomarker discovery process through CDx commercialization.

Who Should Attend

CEOs, Companion Diagnostics Vice-Presidents, Directors, Chief Medical Officers from:

• Companion Diagnostics
• Worldwide Regulatory Strategy
• Biomarkers
• Medical Sciences
• Principal Scientist
• Corporate Development & Ventures
• Global Diagnostic
• Companion Diagnostic Development
• Regulatory Affairs
• Companion Diagnostic Development
• Diagnostic & Experimental Pathology

From Industries Including: 

• Pharmaceutical
• Research Institutes
• Biotechnology
• CD entities